Neurogene Inc. Net Income (Loss) Available to Common Stockholders, Basic
Neurogene Inc. (NGNE) reported Net Income (Loss) Available to Common Stockholders, Basic of -$37.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-09.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2017-03-09
- Neurogene Inc. net income (loss) available to common stockholders, basic for the quarter ending 2015-12-31 was -$5.66M.
- Neurogene Inc. net income (loss) available to common stockholders, basic for the quarter ending 2015-09-30 was -$5.04M.
- Neurogene Inc. net income (loss) available to common stockholders, basic for the quarter ending 2015-06-30 was -$4.75M.
- Neurogene Inc. net income (loss) available to common stockholders, basic for the quarter ending 2015-03-31 was -$6.41M.
- Neurogene Inc. net income (loss) available to common stockholders, basic for fiscal 2016 was -$37.00M.
- Neurogene Inc. net income (loss) available to common stockholders, basic for fiscal 2015 was -$21.86M.
- Neurogene Inc. net income (loss) available to common stockholders, basic for fiscal 2014 was -$23.82M.
- Neurogene Inc. net income (loss) available to common stockholders, basic for fiscal 2013 was -$14.94M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 123 month |
|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | -$37.00M 10-K · filed 2017-03-09 | ||||||||
| 2015-12-31 | -$5.66M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | -$10.70M derived: sum of 2 quarters · filed 2017-03-09 | -$15.45M derived: sum of 3 quarters · filed 2017-03-09 | -$21.86M 10-K · filed 2017-03-09 | |||||
| 2015-09-30 | -$5.04M 10-Q · filed 2015-11-10 | -$9.79M derived: sum of 2 quarters · filed 2015-11-10 | -$16.20M 10-Q · filed 2015-11-10 | -$24.29M derived: sum of 4 quarters · filed 2017-03-09 | |||||
| 2015-06-30 | -$4.75M 10-Q · filed 2015-08-06 | -$11.16M 10-Q · filed 2015-08-06 | -$19.25M derived: sum of 3 quarters · filed 2017-03-09 | -$25.54M derived: sum of 4 quarters · filed 2017-03-09 | |||||
| 2015-03-31 | -$6.41M 10-Q · filed 2015-05-12 | -$14.50M derived: sum of 2 quarters · filed 2017-03-09 | -$20.79M derived: sum of 3 quarters · filed 2017-03-09 | -$26.21M derived: sum of 4 quarters · filed 2017-03-09 | |||||
| 2014-12-31 | -$8.09M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | -$14.37M derived: sum of 2 quarters · filed 2017-03-09 | -$19.80M derived: sum of 3 quarters · filed 2017-03-09 | -$23.82M 10-K · filed 2017-03-09 | -$23.82M 10-K · filed 2015-03-16 | ||||
| 2014-09-30 | -$6.28M 10-Q · filed 2015-11-10 | -$6.28M 10-Q · filed 2014-11-04 | -$11.71M derived: sum of 2 quarters · filed 2015-11-10 | -$15.73M 10-Q · filed 2015-11-10 | -$15.73M 10-Q · filed 2014-11-04 | -$21.01M derived: sum of 4 quarters · filed 2016-03-14 | |||
| 2014-06-30 | -$5.42M 10-Q · filed 2015-08-06 | -$9.45M 10-Q · filed 2015-08-06 | -$9.45M 10-Q · filed 2014-08-11 | -$14.73M derived: sum of 3 quarters · filed 2016-03-14 | -$19.45M derived: sum of 4 quarters · filed 2016-03-14 | ||||
| 2014-03-31 | -$4.02M 10-Q · filed 2015-05-12 | -$4.02M 10-Q · filed 2014-05-13 | -$9.30M derived: sum of 2 quarters · filed 2016-03-14 | -$14.02M derived: sum of 3 quarters · filed 2016-03-14 | -$16.40M derived: sum of 4 quarters · filed 2016-03-14 | -$71.52M 10-Q · filed 2014-05-13 | |||
| 2013-12-31 | -$5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$10.00M derived: sum of 2 quarters · filed 2016-03-14 | -$12.38M derived: sum of 3 quarters · filed 2016-03-14 | -$14.94M 10-K · filed 2016-03-14 | -$14.94M 10-K · filed 2015-03-16 | ||||
| 2013-09-30 | -$4.72M 10-Q · filed 2014-11-04 | -$7.10M derived: sum of 2 quarters · filed 2014-11-04 | -$9.66M 10-Q · filed 2014-11-04 | ||||||
| 2013-06-30 | -$2.38M 10-Q · filed 2014-08-11 | -$4.94M 10-Q · filed 2014-08-11 | |||||||
| 2013-03-31 | -$2.56M 10-Q · filed 2014-05-13 | ||||||||
| 2012-12-31 | -$12.14M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |